1
Nov
2022

AMN Life Science Pvt Ltd

Exhibitor at CPHI Frankfurt 2022 stand 41J51, Finished Dosage Formulations
About Us

AMN Life having an EU, Health Canada & ANVISA Brazil approved facility for General Oral Solid dosage & an EU compliant Beta Lactam oral facility exports its products all across the globe to major countries. With its state-of-the-art R&D center, AMN has successfully completed several tech transfer projects coupled with expertise in developing new formulations for several dosage forms.

With a capacity to produce more than 700 million tabs, 600 million capsules & 15 million suspensions annually AMN provides a vast range of therapeutic categories comprising CNS, Antibiotics, Gastro, Nephrology, Pain Management, Diabetes, and CVS. We also provide a range of injectables, Onco & several other niche products from our partner facilities through in-licensing & out-licensing routes.

  • IN
  • 2017
    On CPHI since
  • 2
    Certificates
  • 500 - 999
    Employees
Company types
Manufacturer/Innovator
Contact info
Event information
CPHI Frankfurt 2022
  • 1-3 November 2022
  • Messe Frankfurt, Germany
  • Visit us at stand 41J51, Finished Dosage Formulations